Results 21 to 30 of about 10,639 (243)
Rescuing the last-line polymyxins: Achievements and challenges [PDF]
, 2021 Antibiotic resistance is a major global health challenge and, worryingly, several key Gram negative pathogens can become resistant to most currently available antibiotics.
Tony Zhou, Q +4 more
core +1 more source
mBio, 2021 Colistin (polymyxin E) and polymyxin B have been used as last-resort agents for treating infections caused by multidrug-resistant Gram-negative bacteria.
Zhizeng Sun, Timothy Palzkill
doaj +1 more source
Structures of the Polymyxins A and the Question of Identity with the Polymyxins M [PDF]
Nature, 1966 THE elucidation of the structures of the polymyxins and the related antibiotic circulin A has so far revealed a remarkable consistency. Polymyxins B1 and B2 (refs. 1 and 2), polymyxins E1 and E2 (identical with colistins A and B, respectively)3,4, and circulin A (ref.
S, Wilkinson, L A, Lowe
openaire +2 more sources
Dissemination of MCR-Type Genes Encoding Polymyxin Resistance in Russia and Across the Globe
Антибиотики и Химиотерапия, 2021 The MCR-type polymyxin resistance gene localized on a mobile genetic element was described was described in 2015 for the first time. Publications, following the first description, demonstrated the global distribution of MCR-type genes and the role of ...
V. A. Ageevets +3 more
doaj +1 more source
Polymyxins leading to nephrotoxicity
, 2023 Drug resistance gram-negative bacteria are the most hazardous type of germ because they cause life-threatening illnesses. Polymyxins are cyclic lipodecapeptide antibiotics that are effective against gram-negative bacteria like Acinetobacter, Pseudomonas,
Lolla, Siddhartha +3 more
core +1 more source
Antibiotics, 2022 Pseudomonas aeruginosa infections are challenging to treat due to multi-drug resistance (MDR) and the complexity of the patients affected by these serious infections.
Aisling R. Caffrey +7 more
doaj +1 more source
Shifting Gears: The Future of Polymyxin Antibiotics
Antibiotics, 2019 The manuscripts contained in this special edition of Antibiotics represent a current review of the polymyxins as well as highlights from the 3rd International Polymyxin Conference, which was held in Madrid, Spain, 25 to 26 April 2018.
Justin R. Lenhard +3 more
doaj +1 more source
Transcriptomic Responses to Polymyxin B and Analogues in Human Kidney Tubular Cells
Antibiotics, 2023 Polymyxins are last-line antibiotics for the treatment of Gram-negative ‘superbugs’. However, nephrotoxicity can occur in up to 60% of patients administered intravenous polymyxins. The mechanisms underpinning nephrotoxicity remain unclear.
Mengyao Li +6 more
doaj +1 more source
Frontiers in Microbiology, 2020 Pseudomonas aeruginosa is an opportunistic human pathogen and a leading cause of nosocomial infections. Due to its high intrinsic and adaptive resistance to antibiotics, infections caused by this organism are difficult to treat and new therapeutic ...
Alessandra Vitale +7 more
doaj +1 more source
Synthesis and Evaluation of Polymyxins Bearing Reductively Labile Disulfide-Linked Lipids [PDF]
, 2022 Polymyxins are a class of lipopeptide anti-infective agents with potent and specific activity against Gram-negative bacteria. While toxicity concerns associated with polymyxin B and E (colistin) have historically limited their clinical application, today
Cornelis J. Slingerland (14069540) +18 more
core +2 more sources